Anumana is a company that is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Pulse 2.0 interviewed Anumana CEO Maulik Nanavaty to learn more about the company.
Anumana: Interview With CEO Maulik Nanavaty About The AI-Driven Health Technology Company
Related Articles
How Doctors Use AI to Help Diagnose Patients
Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially…{post_date: F d, Y}
Anumana’s ECG-AI® Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available{post_date: F d, Y}
Trial demonstrates early AI-guided detection of heart disease in routine practice
Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the…{post_date: F d, Y}
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the…{post_date: F d, Y}